← Back to Search

Nanodropper Device for Glaucoma

N/A
Recruiting
Led By Julius Oatts, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Use of prostaglandin analogue (PGA) eye drop
18 years old or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial compares the effects of two types of eye drops for glaucoma patients.

Who is the study for?
This trial is for adults with stable open-angle glaucoma or ocular hypertension who've been using prostaglandin analogue eye drops. It's not suitable for those who've had recent eye surgery, have uncontrolled glaucoma, acute angle-closure glaucoma, other retinal diseases, or use non-PGA IOP-lowering meds.Check my eligibility
What is being tested?
The study tests the Nanodropper device to see if it's as good as standard eye drops at lowering intraocular pressure in patients with glaucoma. The goal is to prove that smaller drops from this device work just as well without compromising treatment efficacy.See study design
What are the potential side effects?
While specific side effects of the Nanodropper aren't detailed here, typical eye drop-related side effects can include temporary discomfort, redness in the eyes, blurred vision, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am using prostaglandin eye drops.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with open-angle glaucoma or high eye pressure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intraocular pressure (IOP) at Baseline
Intraocular pressure (IOP) at Month 1
Intraocular pressure (IOP) at Month 3
Secondary outcome measures
Conjunctival Grading at Baseline
Conjunctival Grading at Month 3
Survey

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NanodropperExperimental Treatment1 Intervention
Participants will receive the Nanodropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the Nanodropper.
Group II: Standard of Care DropperActive Control1 Intervention
Participants will receive standard of care eye dropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the standard of care eye dropper.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nanodropper
2021
N/A
~50

Find a Location

Who is running the clinical trial?

Icare Finland OyIndustry Sponsor
5 Previous Clinical Trials
714 Total Patients Enrolled
2 Trials studying Glaucoma
189 Patients Enrolled for Glaucoma
University of California, San FranciscoLead Sponsor
2,496 Previous Clinical Trials
11,934,649 Total Patients Enrolled
8 Trials studying Glaucoma
76,751 Patients Enrolled for Glaucoma
Nanodropper, Inc.Industry Sponsor
3 Previous Clinical Trials
500 Total Patients Enrolled
2 Trials studying Glaucoma
450 Patients Enrolled for Glaucoma

Media Library

iCare Clinical Trial Eligibility Overview. Trial Name: NCT05273385 — N/A
Glaucoma Research Study Groups: Nanodropper, Standard of Care Dropper
Glaucoma Clinical Trial 2023: iCare Highlights & Side Effects. Trial Name: NCT05273385 — N/A
iCare 2023 Treatment Timeline for Medical Study. Trial Name: NCT05273385 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still availability for prospective participants in this investigation?

"That is correct. Information available on clinicaltrials.gov indicates that this research trial, which was first made public in October 10th 2022, is actively seeking participants. The project will accept 80 patients from one medical centre."

Answered by AI

How many participants are partaking in this clinical trial?

"Affirmative. According to the latest information on clinicaltrials.gov, this medical study is still enrolling participants. It was initially posted in October 2022 and has since been modified; it seeks 80 individuals for trials at one site."

Answered by AI
~12 spots leftby Dec 2024